Russia debuts first homegrown semaglutide pill for type 2 diabetes

Russia has launched its first locally produced medication for type 2 diabetes based on semaglutide. The drug, named Semaltara, comes in tablet form and is manufactured by pharmaceutical company Promomed. It aims to provide a more accessible treatment option for patients struggling with injections or long-term metabolic management.

The new medication arrives as demand grows for effective diabetes treatments, particularly among patients with overweight or obesity—who make up around nine out of ten cases. Semaltara is produced at the Biokhimik plant, owned by Promomed. It serves as an analogue to a Danish semaglutide medication that has not been supplied to Russia for the past two years. The drug is now available in three dosages: 3 mg, 7 mg, and 14 mg.

GLP-1 agonists like Semaltara work by stabilising blood glucose levels, aiding weight control, and protecting the cardiovascular system and kidneys. Semaglutide, the active ingredient, helps regulate insulin secretion and lowers blood sugar. Unlike injectable treatments, Semaltara tablets offer an alternative for patients who find injections difficult or prefer long-term oral management.

Local production of Semaltara also reduces dependence on foreign supplies. This ensures a steady and uninterrupted access to essential diabetes treatments for Russian patients. The introduction of Semaltara provides a new option for type 2 diabetes management in Russia. Its tablet form and domestic production address both patient convenience and supply stability. The drug is now available for prescription by physicians across the country.